Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Scheinberg

Showing results (311-320 of 426) with videos related to

Pageof 43
Sort By:
Blood|October 1, 1988
Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeadsC Shimazaki, D Wisniewski, D A Scheinberg, et al.
Assay and Drug Development Technologies|December 24, 2011
A high-throughput scintillation proximity-based assay for human DNA ligase IVHui-Min Tseng, David Shum, Bhavneet Bhinder, et al.
Oncoimmunology|March 5, 2016
T cell receptor mimic antibodies for cancer therapyLeonid Dubrovsky, Tao Dao, Ron S Gejman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphomaMaria Lia Palomba, Wendy K Roberts, Tao Dao, et al.
Leukemia|February 8, 2008
A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal diseaseP G Maslak, T Dao, M Gomez, et al.
JCI Insight|September 8, 2020
Solving an MHC allele-specific bias in the reported immunopeptidomeMartin G Klatt, Kyeara N Mack, Yang Bai, et al.
Expert Opinion on Biological Therapy|April 21, 2016
Opportunities and challenges for TCR mimic antibodies in cancer therapyAaron Y Chang, Ron S Gejman, Elliott J Brea, et al.
Cancer|June 19, 2009
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trialNitin Jain, James M Reuben, Hagop Kantarjian, et al.
Oncotarget|February 2, 2017
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphomaPatrizia Mondello, Enrico Derenzini, Zahra Asgari, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 4, 2007
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubesMichael R McDevitt, Debjit Chattopadhyay, Barry J Kappel, et al.
Pageof 43

Showing results (311-320 of 426) with videos related to

Sort By:
Pageof 43
Blood|October 1, 1988
Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeadsC Shimazaki, D Wisniewski, D A Scheinberg, et al.
Assay and Drug Development Technologies|December 24, 2011
A high-throughput scintillation proximity-based assay for human DNA ligase IVHui-Min Tseng, David Shum, Bhavneet Bhinder, et al.
Oncoimmunology|March 5, 2016
T cell receptor mimic antibodies for cancer therapyLeonid Dubrovsky, Tao Dao, Ron S Gejman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphomaMaria Lia Palomba, Wendy K Roberts, Tao Dao, et al.
Leukemia|February 8, 2008
A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal diseaseP G Maslak, T Dao, M Gomez, et al.
JCI Insight|September 8, 2020
Solving an MHC allele-specific bias in the reported immunopeptidomeMartin G Klatt, Kyeara N Mack, Yang Bai, et al.
Expert Opinion on Biological Therapy|April 21, 2016
Opportunities and challenges for TCR mimic antibodies in cancer therapyAaron Y Chang, Ron S Gejman, Elliott J Brea, et al.
Cancer|June 19, 2009
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trialNitin Jain, James M Reuben, Hagop Kantarjian, et al.
Oncotarget|February 2, 2017
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphomaPatrizia Mondello, Enrico Derenzini, Zahra Asgari, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 4, 2007
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubesMichael R McDevitt, Debjit Chattopadhyay, Barry J Kappel, et al.
Pageof 43